search
Back to results

Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer

Primary Purpose

Status
No longer available
Phase
Locations
Study Type
Expanded Access
Intervention
Pemigatinib
Sponsored by
Incyte Corporation
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)

Inclusion Criteria:

-

Exclusion Criteria:

-

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    April 4, 2019
    Last Updated
    April 11, 2022
    Sponsor
    Incyte Corporation
    Collaborators
    H. Lee Moffitt Cancer Center and Research Institute
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03906357
    Brief Title
    Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    April 2022
    Overall Recruitment Status
    No longer available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Incyte Corporation
    Collaborators
    H. Lee Moffitt Cancer Center and Research Institute

    4. Oversight

    5. Study Description

    Brief Summary
    Expanded access of Pemigatinib to treat a single patient with metastatic pancreatic cancer.

    6. Conditions and Keywords

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Pemigatinib
    Other Intervention Name(s)
    INCB054828

    10. Eligibility

    Eligibility Criteria
    Inclusion Criteria: - Exclusion Criteria: -
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Dae Won Kim, MD
    Organizational Affiliation
    H. Lee Moffitt Cancer Center and Research Institute
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer

    We'll reach out to this number within 24 hrs